Ondine Biomedical (LON:OBI) Sets New 52-Week High - Here's Why

Key Points

• Ondine Biomedical shares hit a new 52-week high, trading at C$15.00 during Wednesday’s session before settling at C$14.50.
• The company's market cap stands at C$104.26 million, with a notable P/E ratio of -4.37 indicating losses.
• Ondine Biomedical focuses on photodisinfection-based therapies aimed at preventing serious infections, including those from antimicrobial-resistant pathogens.

Ondine Biomedical Inc. (LON:OBI - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$15.00 and last traded at C$14.50, with a volume of 367199 shares changing hands. The stock had previously closed at C$13.50.

Ondine Biomedical Stock Up 11.7%

The company has a market cap of C$129.42 million, a P/E ratio of -5.42 and a beta of 0.10. The company has a 50-day simple moving average of C$13.29 and a 200 day simple moving average of C$11.10. The company has a current ratio of 1.36, a quick ratio of 8.26 and a debt-to-equity ratio of 25.95.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.